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Nine human mucm genes have been described, which express glycoproteins 
MUCJ,2,3,4,5AC,5B,6, 7,and 8 in various tissues. It has been shown that different mucins are 
expressed in various gastric disease states as compared to the normal. 
In this study histochemical and immunohistochemical methods were used to determine the type 
of mucin and the pattern of staining in 54 patients with a variety of gastric conditions [i.e. normal 
controls, foetal stomachs, chronic active gastritis, low grade dysplasia, intestinal metaplasia 
(associated with gastritis, benign ulcers, dysplasia and cancer), early and advanced intestinal type 
adenocarcinoma, and diffuse adenocarcinoma]. MUCJ-7 antibodies were used in the study, this 
being the first study to all assess seven MUC antibodies in the various conditions. It is also the 
first study to assess the pattern of mucin staining in foetal stomachs. 
Normal controls were immunoreactive for MUC4, 5 and 6 , and gastritis specimens showed 
similar results, although the latter showed more MUCJ immunoreactivity. Whereas early foetal 
stomach showed no MUC immunoreactivity, MUC4, 5 and 6 were present from the early second 
trimester onwards. There was no significant difference between dysplasia and intestinal 
metaplasia, both categories showing expression of MUC2 and 3 predominantly. 
Early intestinal type adenocarcinomas did not show any mucins in the majority of cases. 
Advanced intestinal type adenocarcinomas showed immunoreactivity predominantly for MUCJ, 
5 and 6, as well as MUC2 in some cases. Diffuse adenocarcinomas showed strong positive MUC2 
andMUC6 staining, and in some casesMUC5 and 7. 
In conclusion this study has shown different patterns of mucin immunoreactivity in various 
gastric disease states. Specimens with dysplasia, intestinal metaplasia, late intestinal type 
adenocarcinoma and diffuse gastric cancer were characterized by increased diversity of mucin 
gene expression, whereas early intestinal cancer showed loss of mucin immunoreactivity. 
Key words: Gastric mucm, immunohistochemistry, dysplasia, intestinal metaplasia, gastric 
carcinoma, Helicobacter pylori. 
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CHAPTER ONE INTRODUCTION 
GASTRIC MUCINS 
Structure and function of mucins 
Mucins are a heterogeneous group of highly glycosylated glycoproteins, which form the major 
component of mucus. They are composed of a polypeptide backbone (apomucin), which is 
extensively glycosylated by 0-linked oligosaccharide chains. The 0-linked chains are initiated by 
N-acetylgalactosamine, which links with threonine and serine residues in the protein core [1-6] . 
The oligosaccharides are arranged in a bottle-brush" fashion around the protein core, which 
allows the mucin to bind large amounts of water. The binding of water results in a mucous gel 
that expands rapidly after excretion into the gastric lumen [6] . 
Mucins are synthesized by many different secretory epithelial cells as membrane-bound or 
secreted products [7 ,8] They are a major component of mucous viscous gels and have 
cytoprotective properties. They play a role in mechanical protection, the maintenance of viscosity 
of secretions and in cellular recognition [1]. Mucus also acts as a free radical scavenger, partly 
because of its ability to bind lipids [6]. Gastric mucins, in particular, are needed to protect the 
stomach from damage by low pH and proteolytic enzymes [l , 8]. Bicarbonate ions, secreted by 
the gastric mucosa, are trapped within the mucous gel lining the stomach. It has been shown that 
pH is an important determinant of mucus function, and that movement of HCl through mucus is 
pH dependent . 
Mucin genes 
Mucins are derived from a heterogeneous family of genes [8]. Nine human mucin genes with 
different mucin protein cores have been identified to date (MUC J, 2, 3, 4, 5AC, 5B, 6, 7, and 8) 
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[9-11] . MUC I -7 have been cloned and sequenced with the use of a variety of human organ 
specific cDNA libraries [12-17]. Nucleotide sequencing indicates that the mucin core proteins 
have tandemly repeated peptides with a high percentage of threonine and/or serine and proline, 
and a high content of 0-glycosylation sites [1 ,12,13]. Each of the identified mucins has distinct 
characteristics, being expressed in an organ and cell specific manner [1 ,3,9]. These mucin genes 
have been labelled MUC I - 7 (See table 1 ), and more recently MUC8 has been identified, but no 
details of its sequencing are available. 
The mucin genes are localized in 5 different chromosomes, but there is a clustering of some of 
the mucin genes at 1 lpl5 [18,19] . 
Sites of mucin expression 
MUC 1 is the best characterized mucin gene, and is localized to chromosome lq21-24 [19]. It is 
a membrane associated mucin, also termed polymorphic epithelial mucin [6,15] which is 
expressed in many epithelia, including bronchus, breast, salivary gland, pancreas, prostate and 
uterus. It is sparsely expressed in gastric epithelium [3 ,5-7,20] and is highly expressed in many 
breast cancers [21]. The MUC I gene product shows a high degree of length polymorphism due to 
the presence of different numbers of tandem repeats [20]. In the stomach MUCI has been 
observed in the cytoplasm and apical membrane of the foveolar cells and of a few mucous gland 
cells. In the body of the stomach parietal cells have been shown to stain with MUC I [7] . MUC I 
has, in addition, more recently been found to be expressed in normal and neoplastic haemopoietic 
tissues [22] . 
MUC 2 is expressed in the duodenum, jejunum, ileum, right colon, and weakly in the 
tracheobronchial tree and gallbladder [l , 3, 6]. 
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MUC 3 is expressed mainly in the small intestine, in both goblet cells and absorptive cells [9], 
but also in colon and gallbladder [6]. It has been localised to chromosome 7q22 [19]. 
MUC 4 has been localized to chromosome 3q29 [19] , and is present in normal bronchial and 
colonic mucosa. Most major studies do not show any expression in gastric mucosa [6,12]. 
MUC 5 is a major gastric mucin, being expressed on the surface and in mucous cells of normal 
stomach. It is also expressed in the tracheobronchial tree, gallbladder and endocervix 
[1 ,6,8,12,17,23-25] . MUC 5 was initially divided into three distinct groups, MUC 5A, 5B and 5C. 
MUC5A and M UC5C have since been shown to belong to the same unique gene, and MUC5B to 
a distinct one, andMUC5 has, therefore, been divided into 2 groupsMUC5AC andMUC5B [19]. 
There are high levels of MUC5AC in gastric epithelium, mainly confined to surface foveolar 
cells, and mucous neck cells, but it is not seen in deep gastric glands [1 O] . 
M UC5, together with MUC2 and MUC6 are localized to chromosome llp15.3-15 .5. It appears 
that the 11 p 15 region contains several distinct gene loci for mucins [18, 19]. 
MUC 6 is expressed in mucous neck cells of gastric glands and pyloric gland cells, as well as in 
the gallbladder, Brunner's glands, pancreatic ductules and seminal vesicles [1 ,6,8,12,17 ,24,25] . 
MUC 7 is a low molecular weight mucin, which has been detected in salivary gland [12,13], and 
is localised to chromosome 4 [19]. 
MUC 8 has recently been identified, and is briefly mentioned in recent papers [10,19], but there 
are no details as to where it is expressed. 
MUCI, MUC5 and MUC6 are expressed in gastric mucosa in most studies. Many studies have 
shown weak expression of MUCI , while others found MUCI to be strongly expressed in surface 
mucous cells and mucous neck cells [3 ,5-7,12,20,25,26] . Parietal cells have also shown weak 
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positive staining with the MUCJ antibody [26]. Normal stomach lacks MUC2, MUC3, and 
MUC4, according to most studies [12], but MUC2 and MUC3 are both expressed in intestinal 
metaplasia and have been reported in gastric carcinomas [6]. MUC4 expression has also been 
reported in carcinomas. MUC7 has not been studied in gastric mucosa. 
Table 1. Summary of sites of expression of mucin genes. 
MUCIN 
GENE SITES OF EXPRESSION REF. 
MUCJ Membrane associated mucin with widespread expression 3,5-7,20,21 
throughout the body. Sparse express10n 1ll gastric 
epithelium. Highly expressed in breast carcinoma. 
MUC2 Jejunum, ileum, right colon, weakly in tracheobronchial tree . 1,3,6 
MUC3 Small intestine predominantly. Also colon and gallbladder. 6,9 
MUC4 Bronchus and colon. 6,12 
MUCS Stomach surface and mucous cells. Tracheobronchial tree. 1,6,8,12,17 ,23-
25 
MUC6 Antral glands and gallbladder. 1,6,8,12,17 ,24, 
25 
MUC7 Salivary gland. 12,13 
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Mucins in disease 
It has been shown that different mucins are expressed in diseased states as compared to normal 
[3,12,27]. Abnormalities of gastric mucin have been associated with a number of diseases such as 
atrophic gastritis, peptic ulcer disease, and chronic active gastritis associated with H pylori [8,9]. 
Mucin gene expression is relatively organ specific, and loss of normal mucin gene regulation 
may occur with metaplasia, dysplasia and particularly with malignancy. In intestinal metaplasia 
it has been shown that there is down regulation of the MUC5 and 6 expression in the gastric 
mucosa, with increased expression of MUC2 and MUC3 (intestinal type mucins) [12,11]. It has 
also been shown that intestinal type carcinomas express MUC2 and 3 [12] . Changes in mucin 
expression have been noted in association with malignant transformation, with some carcinoma 
cells expressing aberrant mucin expression, with either an increase in expression or a loss of 
mucin expression [12, 17]. These changes imply that mucin may play a significant role in the 
biological behaviour of cancer cells [20]. Mucins synthesized by cancer cells are thought to 
contribute to cancer invasion and metastasis , via altered cell adhesion and immune recognition 
[4,5,12,28]. Although alterations in mucin are thought to contribute to the biological behaviour of 
cancer it is also possible that alterations in mucin expression may merely be a reflection of the 
biological changes that have occurred. 
The expression of mucin epitopes is modified in carcinomas, mostly due to alterations in 
glycosylation, [7 ,20] but alterations in the apomucin core have also been cited as contributing to 
the tumour mucin phenotype [26] . Abnormal glycosylation results in hypoglycosylated mucins 
that have lost their luminal polarity [3,12,29]. This loss of carbohydrate side chains results in 
exposure of the tandemly repeated protein core which, combined with the loss of luminal 
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polarity, exposes antigenically active epitopes on the surface of these tumours [21] . Altered cell 
adhesion and/ or immune recognition may follow. 
Mucin gene expression has also been shown to play a role in prognosis in some instances. High 
levels of MUCI have been associated with poor survival in breast cancer [21] carcinoma of the 
ampulla of Yater [30] and gastric carcinoma [31,32]. It has been suggested that increased MUC I 
expression in gastric carcinoma is also associated with aggressive features and a poor prognosis, 
[31-33] . In one study [32] this increased aggressiveness was associated only with the diffuse type 
carcinomas, and not with the intestinal type carcinomas. As the diffuse type of cancer is 
associated with a poorer prognosis anyway MUC I expression is unlikely to have independent 
prognostic value. There are conflicting and inconclusive reports from other studies [7] and it 
appears that MUC I expression cannot reliably be used as a prognostic factor in gastric carcinoma 
[7]. Positive MUC 2 expression in gastric carcinomas has been associated with an improved 
prognosis [32,33]. 
Histochemical classification 
Human gastrointestinal mucins have conventionally been classified histochemically as neutral 
mucins, sulphomucins and sialomucins according to their reaction with PAS, High iron diamine 
and alcian blue respectively [34]. Normal gastric mucin is entirely neutral in type, except for a 
small amount of sialomucin production by the mucous neck cells. No sulphomucin is present in 
normal stomachs [35]. 
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Aetiologic factors 
INTRODUCTION 
Gastric carcinoma is one of the most prevalent cancers in the world [36], and despite a declining 
incidence in the USA and Western Europe, as well as in Asian and White populations locally, it 
remains a major killer worldwide [37,38]. There is a particularly high incidence in the Western 
Cape population of South Africa, especially amongst the so-called coloured (mixed race) 
population [39]. This population has the fourth highest incidence in the world with an estimated 
rate of 50-69,9/100 000 [40-42]. 
Aetiologic factors and the pathogenesis of gastric carcinoma are not fully elucidated, but there is 
little doubt that Helicobacter pylori has a very important role to play in gastric carcinogenesis 
(discussed later in the text), and that well defined precancerous entities relating to Helicobacter 
pylori infection exist. Intestinal metaplasia, chronic atrophic gastritis and dysplasia are 
considered to be precancerous lesions and to precede gastric carcinoma in many instances, 
especially the intestinal type adenocarcinomas [43-60]. Factors such as diet, climatic, 
environmental and genetic influences may partly explain the different geographical incidence of 
gastric carcinoma [35]. 
Precancerous lesions 
Intestinal metaplasia is characterized by a change in morphology from a gastric to an intestinal 
phenotype, associated with a change from neutral to acid mucin, and as the process becomes 
more advanced sulphomucins make their appearance [61,62]. Intestinal metaplasia is divided into 
complete IM (type I), which resembles small intestinal epithelium, and incomplete, which 
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resembles colonic epithelium. Incomplete IM is divided into types Ila and Ilb ( or type II and III), 
depending on the presence or absence of sulphomucins [54,56-58,63-65]. Intestinal metaplasia is 
a common association with benign as well as malignant conditions, and this limits its use as a 
selective marker for increased cancer risk [27 ,46-48,54,56-58,66]. It is far too common to have 
any predictive value in an individual patient [61] . Sulphomucin secreting IM (type Ilb ), however, 
is considered to have a higher correlation with subsequent gastric cancer (particularly intestinal 
type adenocarcinoma), than non-sulphated types (types I and Ila) [45-47,56-58,62,64-67], and is 
possibly a marker for malignant change . It is not known for certain whether intestinal metaplasia 
is, in fact, truly precancerous, or merely a parallel response to a carcinogenic environment 
[34,48,50,54,64]. Not only is the histochemical type of mucin in intestinal metaplasia different 
from normal, but mucin gene expression is also altered. There is a decrease in expression of the 
normal stomach mucins MUC5 and 6 in intestinal metaplasia, and an upregulation of M UC2 and 
3 [11]. 
Atrophy of the gastric mucosa is defined as loss of glandular tissue, and it occurs with all 
pathological processes that cause severe mucosa} damage. Extensive chronic atrophic gastritis, 
usually associated with intestinal metaplasia carries an increased risk of malignancy [67, 68] . 
Dysplasia is characterized by architectural disorganization, cellular atypia and abnormal 
differentiation, and is classified as high or low grade [69-71]. Low grade dysplasia (Fig. 1) is 
composed of simple tubules with little branching. Neoplastic cells are pseudostratified, tall 
columnar cells with dense, spindled hyperchromatic nuclei and abundant cytoplasm. Mitoses, if 
present, occupy the superficial half of the mucosa. High grade dysplasia shows a greater degree 
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of architectural complexity of the neoplastic glands, and the cells show pleomorphism, loss of 
polarity and frequent mitoses [72]. High grade dysplasia is generally accepted as a marker of risk 
of malignant change [43,50,64,69-73], being common in stomachs with established carcinomas, 
whereas low grade dysplasia in the majority of cases regresses. [69, 73]. Although most low 
grade dysplasias regress, it has been shown that a small percentage do progress to invasive 
carcinoma [73] . 
Figure 1. Low grade dysplasia of gastric glands with adjacent non dysplastic glands 
(Haematoxylin and eosin stain). 
11 
INTRODUCTION 
The Lauren Classification 
There are a number of classifications for gastric carcmoma, but the most widely used 
classifications in the Western world are the Lauren [74] and WHO classifications [43]. For the 
purpose of this study the Lauren classification was used, and is the only one that will be 
mentioned from here onwards. 
The "Lauren Classification" divides adenocarcinomas of the stomach into two major types, the 
intestinal type and the diffuse type. The intestinal type is composed of well-formed glands, lined 
by mucous secreting epithelium, resembling colonic carcinoma. These tumours are usually well 
demarcated. The diffuse type does not usually demonstrate recognisable glands and is composed 
of poorly cohesive single cells and small groups of cells, which infiltrate widely through the 
stomach, and often have a signet-ring pattern of mucin secretion [35]. 
The intestinal type (Fig. 2) of carcinoma is the most frequent type in countries with a high 
gastric cancer risk, and occurs in an older age group. It is preceded by well defined pre-cancerous 
lesions, such as intestinal metaplasia and atrophic gastritis. A putative sequential precancerous 
process has been described with intestinal type adenocarcinoma. It is postulated that chronic 
active gastritis, usually the result of H pylori infection, may progress to chronic atrophic gastritis, 
to intestinal metaplasia, dysplasia and finally to carcinoma. [60,75-79] . This is a long process in 
general requiring 20-40 years to complete. 
The diffuse type (Fig. 3) occurs in relatively low risk populations and is not preceded by 
intestinal metaplasia or other defined precancerous lesions [12,38,43,46,62]. It is the type of 
carcinoma most commonly seen in young persons [3 5]. Although environmental factors are 
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important in this type of cancer it seems that genetic influences have a more important role to 
play [79]. 
CLASSIFICATION OF GASTRIC CARCINOMA 










Figure 2. Intestinal type adenocarcinoma (H & Estain). 
Figure 3. Diffuse type adenocarcinoma infiltrating between the ]ayers of the muscu1aris propria. 
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THE ROLE OF HEL/COBACTER PYLORI IN GASTRIC DISEASE, AND ITS EFFECT 
ON GASTRIC MUCIN. 
Disease processes associated with Helicobacter pylori 
The presence of curved and spiral organisms in the stomach has been reported in the literature for 
many years, but they were not initially considered to be pathogenic. In 1982 Marshall [80] 
isolated these organisms, and named them Campylobacter pylori, the name later being changed to 
Helicobacter pylori. Helicobacter pylori is a gram negative, microaerophilic, curved bacillus, 
[80,81] which is found in gastric mucus in close apposition to the gastric mucosa [82] (Fig. 5). 
Infection with Helicobacter pylori is the most important cause of chronic active gastritis (Fig. 4) 
worldwide, and is associated with evolution to chronic atrophic gastritis and intestinal metaplasia 
at a later stage. It is also associated with gastric and duodenal ulcers, and there is general 
agreement that Helicobacter pylori increases gastric cancer risk. There is a link between 
Helicobacter pylori infection and gastric cancer of both intestinal and diffuse histological types. 
[37,59,60,76,83]. Helicobacter pylori associated gastritis is more frequently located in the 
antrum, [25,59,67,75,81,84,85], but atrophy, intestinal metaplasia and carcinomas occur in both 
the antrum and the body. Helicobacter pylori associated carcinomas are rarely present in the 
cardia. [37]. A large study from Italy [59] showed an eighty five percent incidence of 
Helicobacter pylori colonization in patients with early gastric carcinomas. This percentage 
underscores a highly significant association between Helicobacter pylori and gastric cancer [86]. 
Helicobacter pylori infection is common worldwide, but is particularly prevalent in 
underdeveloped countries, where most adults are infected [86] . The majority of these infections 
are asymptomatic. The present incidence in Cape Town is known to be high, and there are 
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ongoing studies to establish the incidence, and the relation with gastric carcinoma in the local 
population (Louw et al , personal communication, 1999). In South Africa there have been studies 
from Natal which showed an incidence of Helicobacter pylori in seventy nine percent of patients 
undergoing routine endoscopy, with up to ninety five percent of the patients with gastritis having 
Helicobacter pylori, and ninety percent of patients with duodenal ulcers, and fifty percent of 
patients with gastric ulcers demonstrating the organism [87 ,88] . Previous observations from an 
outpatient population in Cape Town showed an overall incidence of seventy three percent [89] . 
The incidence of Helicobacter pylori infection has been shown to increase with age [81] . 
Figure 4. Chronic active gastritis. There are numerous plasma cells in the lamina propria, and 
neutrophils are seen infiltrating the glandular epithelium. (H & Estain). 
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Figure 5. Helicobacter pylori adherent to the gastric mucosa (Giemsa stain). 
Adherence to the mucosa 
Helicobacter pylori is located primarily within the adherent mucus barrier of the gastric mucosa, 
(Fig. 5) but the bacteria may also adhere to the gastric surface mucous cells [25,90]. Colonisation 
usually takes place on normal gastric epithelial surfaces, and Helicobacter pylori does not in 
general adhere to areas of intestinal metaplasia or advanced atrophy in the stomach. In 
specimens showing gastritis with advanced intestinal metaplasia, or with gastric atrophy 
Helicobacter pylori are often undetectable, even if there is evidence of serologic evidence of 
infection [85,91] . 
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The reason for the preferential colonisation is uncertain, but it may be that the acid mucins 
produced by intestinal metaplasia are toxic to Helicobacter pylori, and that the evolution of 
intestinal metaplasia is a defensive mechanism by which the gastric mucosa eliminates 
Helicobacter pylori [75]. There have been some studies, however, which have shown adherence 
of Helicobacter pylori to metaplastic cells in type ill (incomplete, sulphomucin-producing) 
intestinal metaplasia [84,91,92], but not to areas of intestinal metaplasia which don't produce 
sulphomucins. This study would suggest that sulphomucins may not be as toxic as sialomucins to 
Helicobacter pylori, and perhaps may in some way promote the growth of Helicobacter pylori. 
This is of interest because it is this type of intestinal metaplasia that is linked to the development 
of gastric carcinoma. This finding suggests that adherence of Helicobacter pylori plays a role in 
the progression of metaplasia to dysplasia and carcinoma. Other studies are, however, at variance 
with this finding [75], with fewer Helicobacter pylori being detected in association with type ill 
intestinal metaplasia. 
Once invasive carcinoma has developed it seems that the neoplastic environment becomes 
inhospitable to Helicobacter pylori [75], and the organisms are hardly ever seen in association 
with the mucosa in patients with advanced carcinomas. 
Pathogenic mechanisms in Helicobacter pylori associated gastric disease 
Helicobacter pylori infection leads to gastric disease as a result of epithelial damage caused by 
active ongoing inflammation. A multi.step sequence of events leading to the development of 
intestinal type gastric carcinoma has been postulated, in which chronic active gastritis ,if 
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untreated, leads to chronic atrophy, intestinal metaplasia, dysplasia and then finally to carcinoma. 
[75-77,81]. The relationship between Helicobacter pylori and diffuse type gastric carcinoma 
does not seem to follow the same route as with intestinal type carcinomas. Studies have shown 
that DNA damage due to oxygen radicals induced by persistent inflammation resulting for 
Helicobacter pylori infection may play a role in the development of diffuse type gastric cancer 
[76]. 
The exact mechanism for the pathogenesis of Helicobacter pylori induced gastric disease is not 
well understood, but it appears that the organism may injure the gastric epithelium by impairing 
the effectiveness of the protective function of mucins [90] . Helicobacter pylori adversely affects 
the chemical and physical properties of the mucus layer, with alteration of the general quantity 
and quality of mucin, resulting in diminished gel forming properties of the mucin[8], and 
decreased viscosity [93,94] . It appears that Helicobacter pylori per se causes decreased 
polymerization of the mucus gel [95], but according to one study does not cause a decrease in the 
actual thickness of the mucus layer, except where there is significant atrophic gastritis or 
ulceration.[95]. The ability of Helicobacter pylori to degrade mucin is controversial with 
conflicting results from various studies [25,95]. Alterations in the glycosylation process of the 
mucin have been shown to have an effect on the structure and function of mucins and might 
affect their ability to maintain an effective barrier in the stomach [90]. It has been postulated that 
Helicobacter pylori can induce alterations in the gastric mucus by abnormal glycosylation of the 
mucin. The changes in glycosylation would bring about altered expression of carbohydrate 
antigens on the gastric surface. The pattern of glycosylation has been shown to return to normal 
after treatment of the Helicobacter pylori [90]. Urease produced by Helicobacter pylori has been 
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shown to be an aetiologic factor in mucus breakdown. [86,96] Helicobacter pylori secrete urease 
and other proteolytic enzymes, which may have important pathogenic effects. Alterations in the 
mucus layer by whatever mechanism may interfere with the pH gradient in the mucus layer, 
exposing the surface epithelium to excessive hydrogen ions, and therefore leading to further 
damage [ 6] . In one study by Markesich et al [97] the authors argue against degradation and 
decreased viscosity of mucus in Helicobacter pylori infection, but their results differ from most 
other studies. 
In addition to causing alterations in the mucus layer Helicobacter pylori has also been shown to 
induce gastric epithelial proliferation, either directly or indirectly, which is suggestive evidence 
that it may be an initiating step in the development of gastric carcinogenesis [77]. Helicobacter 
pylori infection alone is insufficient to account for gastric carcinoma, as numerous people having 
H pylori infection never develop gastric carcinoma. Dietary factors probably also play a role. [37] 
Age at infection probably also is important, earlier acquisition of the infection being associated 
with an increased incidence of carcinoma [37,78] . 
The effect of Helicobacter pylori on mucin gene expression 
There have not been many studies of the effect that Helicobacter pylori has on expression of 
individual mucin genes in gastric mucosa, but one study has shown that Helicobacter pylori 
infection does cause abnormalities of mucin gene expression [25] . In this study it was shown that 
Helicobacter pylori caused aberrant expression of MUC6 in surface mucous cells , where it is not 
normally expressed, and that there was significantly less than normal MUC5 expression in the 
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surface mucous cells. Aberrant expression of mucm could facilitate the adherence of 
Helicobacter pylori to the epithelial surface, and promote dissolution of the protective mucous 
barrier. The study also showed that eradication of Helicobacter pylori in these cases caused a 
reversion of the mucin expression to normal [25]. 
AIMS OF THIS STUDY 
1. The main aim of this study is to examine the different types of mucin expressed in normal 
stomachs, and in various gastric disease states. 
2. Gastric carcinoma is often detected very late in our community and another aim of the study is 
to attempt to show if there is any use for mucin immunohistochemistry in detecting 
precancerous states and early cancer, and therefore aiding in earlier diagnosis. 
3. The third aim is to assess the association of Helicobacter pylori with the various non-neoplastic 
and neoplastic disease states in the stomach. 
21 
CHAPTER TWO MATERIALS AND METHODS 
In this study histochemical and immunohistochemical methods were used to determine the type 
of mucins present, and the pattern of mucin immunoreactivity in the stomach in a variety of 
conditions. These included normal gastric controls, foetal stomachs, stomachs with chronic active 
gastritis, low grade dysplasia, intestinal metaplasia ( associated with benign ulcers, dysplasia and 
cancers), early and advanced intestinal type adenocarcinoma, and diffuse adenocarcinoma. 
Selection of cases. 
Gastric tissue from a total of 54 cases was specifically selected from recent laboratory material. 
These included five normal controls, six foetal stomachs (two were under 12 weeks' gestation and 
four were over 12 weeks' gestation), nine cases of chronic active gastritis (three with associated 
intestinal metaplasia), seven mild dysplasias (all of which had associated intestinal metaplasia), 
nine benign ulcers (six with associated intestinal metaplasia), six early intestinal type 
adenocarcinomas (five with associated intestinal metaplasia), five advanced intestinal type 
adenocarcinomas (two with associated intestinal metaplasia) and seven diffuse adenocarcinomas. 
In total twenty three cases had intestinal metaplasia as one of the abnormalities. Two of the 
normal controls were biopsies, and three were from cadaveric organ donors who had no known 
underlying pathology in other organs. The foetal material was derived from autopsies. The 
chronic active gastritis cases were all biopsies, as were all the dysplasias except for one which 
came from a gastrectomy specimen. The ulcer specimens were all obtained from partial 
gastrectomies, and all the carcinoma samples were derived from gastrectomy specimens. 
Mild gastric epithelial dysplasia was characterized by low grade cellular atypia, slight nuclear 
stratification, and an increased nuclear/cytoplasmic ratio, as well as mild architectural 
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derangement [38]. Early carcinomas were defined as those that had not penetrated the muscularis 
propria [43] (Fig. 6). 
Figure 6. Early intestinal type adenocarcinoma confined to the mucosa (H & E stain). 
Histochemistry 
Representative paraffin-embedded tissue blocks were recut to provide 2um thick sections. These 
were stained with routine haemotoxylin and eosin [98], Giemsa to detect Helicobacter pylori, and 
special stains for the determination of mucin type i.e. Periodic acid -Schiff (PAS), for the 
detection of neutral mucins; Alcian Blue (pH 2.5), which stains acid (sialo) and most sulphated 
mucins blue; Mucicarmine, for the detection of acidic (sialo) mucins, and High iron 
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Diamine [98] . The latter stain was used to differentiate sulphated mucins (which stain black) 
from non - sulphated mucins (which stain blue) [44,63,99]. 
lmmunohistochemistry. 
Antibodies for this study (MUCJ-7) were kindly provided by Professor Sam Ho (University of 
Minnesota and Veterans Administration Medical Center, Minneapolis) [see appendix]. For 
immunohistochemical staining 2um sections were cut and placed on glass slides coated with 3-
aminopropyltriethoxysilane (APES). Sections were incubated at 37 degrees overnight, and then 
dewaxed and rehydrated. 
Endogenous peroxidase activity was quenched with a 1 % hydrogen peroxide methanol solution 
for 15 minutes at room temperature. After washing 3 times in phosphate buffered saline (PBS) 
those tissues requiring antigen retrieval were microwaved in citrate buffer (pH 6.0) for 10 
minutes on full power ( 600 watts) [ 98] . 
Each section was stained immuno-enzymatically in a humidity chamber using a modified 3 step 
peroxidase conjugated avidin-biotin method [98]. Non-specific binding was blocked with non-
immune serum (swine, rabbit or chicken) at a 1 :20 dilution for 10 minutes. Optimal dilutions of 
the Primary antibodies were determined using the "checkerboard titration" method [98,100]. 
Sections were washed thoroughly in PBS after each antibody incubation. The sections were 
subsequently incubated with a 1 :250 biotinylated rabbit-anti-mouse, swine anti-rabbit (Dako, 
Copenhagen, Denmark), or rabbit-anti-chicken 1:500 (Biogenesis, Poole, U.K.) antibody for 30 
minutes at room temperature and then with a strep-avidin HRP (Dako, Denmark) for 30 minutes. 
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After washing, peroxidase activity was detected using 3.3' diaminobenzidine (Sigma, St Louis, 
U.S.A.) as a chromagen with 1 % hydrogen peroxide solution as the substrate. Sections were 
washed to arrest the reaction after 10 minutes, counterstained with haematoxylin, blued in Scott's 
tap water substitute and then dehydrated through graded ethanols to xylol and mounted in a 
synthetic resinous medium. 
The above method [98] was used for MUC 1-7 and for FHF, which is a deglycosylated mucin for 
MUC 5 and 6 [12]. Positive immunohistochemical staining is considered to be cytoplasmic 
staining of more than 50% of the cells in the various conditions examined. In cases where 
staining was less than 50% or was very weak this is reported in the text. 
Positive controls were from normal tissues known to express the relevant antibody. Normal 
breast was used for MUCJ, colon for MUC2 and MUC4, small intestine for MUC3, stomach for 
MUC5 and MUC6, and salivary gland for MUC7. Negative controls, using the same tissues as 
for the positive controls were incubated with no primary antibody, and then they were incubated 
with primary antibody, but no link antibody. In a third step the controls were incubated with 
strep-avid.in to ensure that there was no non-specific linking of primary antibody to the tissues. 
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All cases studied had evidence of Helicobacter pylori infection, except normal controls (n=5), 
foetal stomachs (n=6), diffuse adenocarcinomas (n=7) and 3 of 5 advanced intestinal 
adenocarcinomas. The organism was found in the mucus on the surface of the gastric epithelium, 
and attached to the gastric epithelium. It was seen in biopsies with intestinal metaplasia, but not 
attached to the portion of the epithelium showing metaplastic change. Although Helicobacter 
pylori were not seen in the advanced carcinomas, it is unlikely, considering the high prevalence 
of Helicobacter pylori in our population that the advanced carcinomas never had H. pylori 
infection. It has been shown previously (25] that the environment associated with advanced 
adenocarcinomas is unsuitable for the continued presence of these organisms. 
Histochemical stains 
(The results are summarised in table 2). 
Normal stomachs all stained with neutral mucin as expected, and there was no significant staining 
for acidic mucin. 
Foetal stomachs in the first trimester showed no mucin staining, but neutral mucin was positive 
from the second trimester onwards. 
Chronic active gastritis specimens all showed neutral mucin staining. Acidic mucin was only 
demonstrated in foci of associated intestinal metaplasia. No sulphomucin was detected in the 
intestinal metaplasia associated with gastritis. 
The low grade dySJ)lasias stained positively for neutral and acidic mucins, and half of them 
showed the presence of sulphomucin. 
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In the intestinal metaplasia group there was positive staining for neutral and acidic mucins in all 
cases (Fig 8a & b, and 9). Sulphomucin was present in the goblet cells in 14 of 23 cases. (Fig. 7). 
Of the cases of intestinal metaplasia associated with sulphomucin, 4 were associated with early 
gastric intestinal type adenocarcinoma, 2 with advanced intestinal type adenocarcinoma, 2 with 
benign ulcers, and 6 were associated with dysplasia. Although the numbers are small there does 
seem to be a higher incidence of sulphomucin in association with gastric cancer and with 
dysplasia, compared to gastritis and benign ulcers. The majority of intestinal metaplasia cases 
associated with ulcers (n = 6) displayed no sulphomucin staining, and there was no sulphomucin 
in the intestinal metaplasia associated with gastritis (n = 3). 




Figure 8. Intestinal metaplasia stained with (a) alcian blue and (b) mucicarmine. 
Figure 9. PAS stain showing intestinal metaplasia (left) adjacent to normal gastric mucosa. 
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Table 2. Results of Histochemical staining in normal and diseased states. 
N FS* G D IM IAC AIAC DAC 
No of cases 5 6(4/6>12 9 7 23 6 5 7 
weeks) 
Neutral mucin 100% 100% 100% 100% 100% 83% 80% 86% 
Acidic/sulphated 0% 0% 0% 100% 100% 50% 60% 50% 
mucms 
Acidic mucins 0% 0% 0% 100% 100% 33% 60% 50% 
Sulphated 0% 0% 0% 57% 61% 0% 40% 16% 
Abbreviations: N, normal stomachs; FS, foetal stomachs; G, gastritis: D, low grade dysplasia; IM, intestinal 
metaplasia; IAC, early intestinal type adenocarcinoma; AlAC, advanced intestinal type adenocarcinoma; DAC, 
diffuse adenocarcinoma 
*Foetal stomachs in the first trimester showed no mucin expression at all. The figures in the table are for foetal 
stomachs after 12 weeks. 
Early intestinal type adenocarcinomas showed staining for neutral mucin in 5 of 6 cases, and 
staining for acidic mucin in 2 of 6 cases with the Alcian blue stain, and in 3 of 6 cases with 
muc1carmme. 
Advanced intestinal type adenocarcinomas showed neutral mucin in 4 of 5 cases, acidic mucin in 
3 of 5 cases, and sulphomucin in 2 of 5 cases. 
The diffuse adenocarcinomas showed neutral mucin in 6 of 7 cases, acidic mucin in 2 of 7 cases 




(The results are summarised in table 3.) 
For origins of the antibody clones see appendix. 
MUC I showed weak positive staining in only one of five normal stomachs. The staining was in 
the superficial mucous cells of the foveolae, in surface mucus and in the parietal cells. The 
majority of cases of gastritis (8 of 9) showed positive staining with MUC 1. MUC 1 was present 
predominantly in surface mucus and in superficial glands, and in three cases there was staining in 
the foveolar mucous cells as well. There was positive staining in four of five advanced intestinal 
adenocarcinomas (see Fig. 18a). The remaining categories showed no staining. 
MUC 2 showed patchy positive staining in 60% (3 of 5) of normal stomachs, predominantly in 
mucous neck cells; no staining in early foetal stomachs, and positive staining in foveolar mucous 
cells in 50% (2 of 4) of foetal stomachs after 12 weeks of gestation. There was patchy positive 
staining in foveolar mucous neck cells in 2 cases of gastritis, and in one case the parietal cells 
stained positively. Mucous cells in dysplastic glands showed positive staining in all the low grade 
dysplasias (Fig. 10), and there was also MUC2 staining in all the intestinal metaplasias (Fig. 11 ), 
the staining being confined to the goblet cells. There was very focal staining in 33% (2 of 6) of 
early intestinal type adenocarcinomas, positive staining in 60% (3 of 5) of advanced intestinal 
adenocarcinomas ( although in one case the staining was weak and focal) and strong staining in 
85% (6 of?) of diffuse adenocarcinomas (Fig. 17a). 
MUC 3 showed no staining in normal stomachs, and focal staining in foveolar mucous cells in 
25% (1 of 4) of the second trimester foetal stomachs. There was no significant staining in 
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gastritis. There was positive staining in 71 % (5 of 7) of dysplasias and in 56% (13 of 23) of the 
intestinal metaplasias, within goblet cells, focal staining in 16% (1 of 5) of early intestinal 
adenocarcinomas, no staining in advanced intestinal adenocarcinomas and staining in 29% (2 of 
7) of diffuse adenocarcinomas. 
Figure 10. Positive MUC2 staining in low grade dysplasia. 
Figure 11. Positive MUC2 staining in intestinal metaplasia. 
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MUC 4 showed positive staining in mucous neck cells and strong staining in basal mucous glands 
in 100% ( 5 of 5) of normal stomachs. (Figs. 12 and 13 ). There was no staining in first trimester 
foetuses, but positive staining was present in 75% (3 of 4) of second trimester foetal stomachs, 
the staining in the latter being weak surface and mucous gland staining. There was positive 
staining in all cases of gastritis, the staining pattern being the same as that of normal controls. In 
dysplasias there was weak, variable staining in 42% (3 of 7), weak patchy staining in 22% (5 of 
23) of intestinal metaplasias, no staining at all in early intestinal type adenocarcinomas, weak 
staining in 20% (1 of 5) of advanced intestinal adenocarcinomas and no staining in diffuse 
adenocarcinomas. Where residual 'normal' basal glands were present in any of these conditions 
there was positive staining with MUC 4. 
Figure12. Normal stomach showing positive staining with MUC4 (lOOx magnification) 
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Figure 13. MUC4 staining at 400x magnification. Same case as figure 12. 
MUC 5 showed weak positive staining in 60% (3 of 5) of normal stomachs, in mucous neck cells 
and basal mucous glands; no staining in first trimester foetal stomachs and positive staining in 
75% (3 of 4) of second trimester stomachs, mainly surface staining. All cases of gastritis showed 
positive staining with MUC5. The staining was found predominantly in the surface mucous cells 
and the foveolar neck cells, but in 6 cases also in the basal glands. There was positivity in 14% (1 
of 7) of dysplasias, variable staining in 38% (7 of 18) of intestinal metaplasias, no staining in 
intestinal type adenocarcinomas, and positive staining in 60% (3 of 5) of advanced intestinal 
adenocarcinomas and in 57% ( 4 of 7) of diffuse adenocarcinomas. (Fig. 17b) 
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MUC 6 showed staining in 80% (4 of 5) of normal stomachs (Fig. 14), predominantly in gastric 
surface epithelial cells and gastric mucous neck cells. The presence of MUC6 in the mucous neck 
cells corresponds with the findings in other reports [1 , 8,25], but MUC6 is usually not found in 
the surface mucous cells [8,25]. There was no MUC 6 staining in first trimester foetal stomachs, 
but there was predominantly surface staining in second trimester stomachs (Fig. 15). 89% (8 of 9) 
of gastritis cases showed positive staining with MUC6, the staining being similar in distribution 
to that MUC5. Positive staining was seen in 29% (2 of 7) of dysplasias, in 17% (4 of 23) of 
intestinal metaplasias, in none of the early intestinal type adenocarcinomas (Fig. 16), in 80% ( 4 
of 5) of advanced intestinal adenocarcinomas (Fig. 18b) and in 85 % ( 6 of 7) of diffuse 
adenocarcinomas (Fig. 17 c ), the latter showing strong positive staining. 
Figure 14. Normal stomach showing positive staining of gastric antral glands with MUC6. 
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Figure 15. Foetal stomach (gestational age 14 weeks) showing positive staining with MUC6. The 
staining is seen on the surface of the stomach and in glands. 
Figure 16. Early intestinal type adenocarcinoma showing no staining with MUC6. 
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MUC 7 showed staining in 40% (2 of 5) of normal stomachs. The staining was found mainly in 
the mucous neck cells, but also in parietal cells in one case, and in neuroendocrine cells in most 
cases. There was surface staining in 50% (2 of 4) of second trimester foetal stomachs, positive 
staining in 78% (7 of 9) of gastritis cases, 57% (4 of 7) of dysplasias, and in 35% (8 of 23) of 
intestinal metaplasias, no staining in early or advanced intestinal type adenocarcinomas, and 
positive staining in 57% ( 4 of 7) of diffuse adenocarcinomas (Fig. 17d). 
FHF (rabbit polyclonal antibody), which is an antibody to deglycosylated gastric mucins (MUC5 
and MUC6 core peptides) showed strong positive staining in all groups, except in early foetal 
stomachs, and is therefore considered to be unhelpful in this study. 
It was noted that the distribution of MUC 2 in the majority of cases correlated very closely with 
that of sialomucin. This was best assessed in intestinal metaplasia where there was striking 
MUC2 positivity as well as abundant sialomucin. No definite correlation between MUC2 and the 
presence of sulphomucin could be made . Very weak staining with MUC4, 5, and 6 was also 
present in some instances in areas where sialomucin was present, but the strength of MUC2 
staining was much greater than any of these and it would appear that MUC2 therefore correlates 
with the presence of acidic (sialo)mucin. 
These results have been published in Oncology Research 10: 465-473, 1998. [101] 
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Table 3. Results of MUC antibodl'. exnression in normal and diseased states. 
N FSa G D JM> IAC AIAC DAC 
No. of 6(4/6>12 
cases 5 weeks) 9 7 23 6 5 7 
MUCJ 20% 0% 89% 0% 0% 0% 80% 0% 
MUC2 60%1 50% 22% 100% 100% 33%2 60% 85% 
MUC3 0% 25%2 0% 71% 56% 16%2 0% 29% 
MUC4 100% 75% 100% 42%1 22%1 0% 20%1 0% 
MUC5 60%1 75% 100% 14% 30% 0% 60% 57% 
MUC6 80% 75% 89% 29% 17% 0% 80% 85% 
MUC7 40% 50% 78% 57% 35% 0% 0% 57% 
"Foetal stomachs in the first trimester showed no MUC gene product expression at all. The figures listed in the table 
are for foetal stomachs after 12 weeks (second trimester). 
bOf the 23 cases of IM 6 were associated with benign ulcers, 3 with gastritis, 7 with low-grade dysplasia, 5 with 
early intestinal adenocarcinoma, and 2 with advanced intestinal adenocarcinoma. 
1The staining in these conditions was weak, and sometimes quite variable. 
1'hese cases showed only focal staining. 
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Figure 17. Diffuse adenocarcinomas showing multiple expression with (a) MUC2, (b) MUC5, 
( c) MUC6, and ( d) MUC7. 
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Figure 18. Advanced intestinal type adenocarcinomas showing expression of (a) MUCJ and (b) 
MUC6. 
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Discussion of results and comparison to other studies 
This is the first study to systematically examine all the MUC antibodies in human gastric 
mucosa, in normal, foetal and disease states by histochemical and immunohistochemical 
methods. Some of the immunohistochemical results in this study differ from those of previous 
studies. The following discussion, therefore, makes comparisons with other studies and sets out 
to show the validity of the findings in this study. 
The histochemical findings are similar to those of other studies, which have shown that 
sialomucins are not found in appreciable amounts in normal gastric mucosa, gastric mucins 
being predominantly neutral [99], and that sialomucins are prominent in intestinal metaplasia 
[44,102]. 
Intestinal metaplasia, chronic active gastritis, and dysplasia have been shown to precede gastric 
carcinoma in many instances, particularly the intestinal type of adenocarcinoma [43-60] .This has 
been discussed in more detail in the introduction. In this study a high association of sulphomucin 
secreting intestinal metaplasia with intestinal type adenocarcinoma was found (i .e 6 of 7 cases), 
which correlates with other studies, and a lower incidence was associated with gastritis (0 of 3) 
and benign ulcers (2 of 6). In addition all the cases of intestinal metaplasia associated with mild 
dysplasia showed the presence of sulphomucins. High grade dysplasia has been shown to have a 
higher risk of subsequent carcinoma, particularly intestinal type adenocarcinoma 
[38,43,50,64,71] . Mild dysplasia in itself is not thought to be an increased cancer risk [49] , but 
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the fact that it has occurred together with type lib intestinal metaplasia should perhaps alert one 
to follow these particular patients more carefully than if they had mild dysplasia alone. Further 
study is required in this area. 
Sulphomucin positivity has been frequently observed in carcmomas [63,57]. Although the 
intestinal metaplasias in association with the cancers in this study showed sulphomucins only 
three of the cancers themselves showed a small amount of sulphomucin staining. 
Human gastric mucosa has a specific mucin gene pattern that differs from that of other mucin-
gene producing organs in the body [1 ,12] . In the following paragraphs the results of the 
immunohistochemical studies are discussed. In some respects these results correspond with other 
studies, but there are some differences. 
Normal control stomachs were predominantly characterised by expression of MUC 4, 5 and 6 
predominantly. Previous reports [12] have shown MUC I expression in normal gastric 
epithelium. Sakamoto et al [31] showed expression ofMUCJ predominantly in fundic glands and 
in parietal cells of normal stomachs. Weak MUC I staining was only demonstrated in 20% of the 
normal controls in this study, which may be due to a technical problem. There was, however 
positive staining in 80% of the advanced intestinal adenocarcinomas, so that the lack of staining 
in the normal controls is difficult to explain, and needs further elucidation. The fact that most of 
the. normal control material was obtained from cadaveric donors might be one explanation, as 
fixation may have been suboptimal. MUCJ is thought to play an important role in tumour 
development [103], so that increased expression in the advanced adenocarcinomas in this study is 
not unexpected, and, in fact, supports its involvement in tumourigenesis. MUCJ was also 
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positive in a large proportion of the gastritis cases. It is not possible to reach any definite 
conclusions as to the cause of this . 
MUC 4, on the other hand, was expressed strongly and unequivocally in all normal stomachs, 
particularly in basally situated glands. This finding differs from some of the early studies in 
which MUC4 was not found to be expressed in the stomach [8,12] , MUC4 has, however, since 
been reported by a number of researchers. It was first reported by the author and colleagues in an 
abstract in 1996 (104). The presence of MUC 4 in these cases appears genuine, as it was 
consistently and repeatedly positive in all normal stomachs. The whole MUC4 gene has only 
recently been sequenced by Moniaux et al. (105), and these authors have now also reported 
findingMUC4 in the stomach, in addition to the colon, cervix and lung. MUC4 has been found in 
adult tissues, as well as in epithelial cells in embryos and foetuses. MUC4 has been reported by 
Bui sine et al (106), as being the first gene to be expressed in the fore gut, where it can be detected 
as early as 6,5 weeks. 
MUC5 and MUC6 positivity in normal stomachs was similar to previous studies, except for the 
presence of MUC6 in surface mucous cells, a finding that differs from other studies [8,25]. One 
study [25] has shown that Helicobacter pylori can induce surface mucin expression, but the 
normal controls in this study did not have histologically proven infection with Helicobacter 
pylori, and the reason for surface MUC6 staining is uncertain. 
MUC7 staining in neuroendocrine cells in normal control stomachs is unexplained. This has not 
been previously reported. It may be related to antigen retrieval methods, and is possibly a heat 
related artefact. 
Foetal stomachs, in this study, were shown to have similar mucin gene expression to adult 
stomachs, but only from the second trimester onwards. 
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Disease processes in the stomach are associated with significant alteration in expression of 
gastric mucin genes. This was clearly shown in the study by Ho et al [12], who studied 
expression of MUC 1 - 6 mucin genes in normal and diseased gastric epithelium. Other studies 
have shown increased expression of poorly defined antigens that occur in gastric cancer and 
intestinal metaplasia, but not in normal epithelium. Such antigens as SIMA and LIMA [27 ,52] are 
described, which may coincide with certain MUC genes, but thus far have not been identified as 
such. In a study by Filipe et al [27] it was shown that LIMA (large intestinal mucin antigen) was 
expressed :in intestinal metaplasia and dysplasia in carcinoma bearing stomachs. Gastritis cases, 
in this study, showed similar immunoreactivity to normal stomachs, with MUC4, 5, and 6 
staining, but there was also a greater amount of MUCJ and 7 present. This study found that 
MUC 2 and 3 expression is increased in intestinal metaplasia, corresponding with previous 
reports [12]. This was the case :in all cases of IM whether it was associated with ulcers, dysplasia 
or malignancy. Mild dysplasias show a similar staining pattern to intestinal metaplasia in this 
study, and muc:in gene product expression therefore does not assist :in distinguishing one from the 
other. It was interesting to note that MUC2 expression correlated with the presence of 
sialomuc:ins. This was best assessed :in cases of intestinal metaplasia, but could also be 
demonstrated in other categories. 
Gastric cancers in this study showed striking differences in mucin gene expression as compared 
to the normal. Loss of mucin gene expression in early intestinal type adenocarcinomas was 
unexpected. There is a previous report of loss of mucin production in cancers, but these cancers 
were generally late cancers or less well differentiated cancers [52]. Very early cancers were not 
studied in other papers. Corresponding positive controls of intestinal metaplasia were present in 
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most of the early carcinoma specimens in this study, proving that the lack of staining does not 
have a technical basis. 
Positive staining with multiple mucin antibodies was, however, found in the advanced intestinal 
type adenocarcinomas and in the diffuse adenocarcinoma group, and this corresponds with 
previous findings [12,27]. There is also considerable heterogeneity between different cancers in 
these two groups. MUC 1, 5 and 6 were identified most strongly in the advanced intestinal type 
adenocarcinomas, with variable expression of MUC 2 in some cases. MUC2, 5, 6 and 7 were 
expressed in various combinations in a large proportion of diffuse adenocarcinomas. Apart from 
one of the advanced intestinal type adenocarcinomas showing weak MUC4 staining, there was a 
striking absence of MUC4 staining in the latter two groups. Ho et al [12] showed that there was 
increased expression of mucin genes with advanced cancers as compared to early cancers, and 
that there was increased expression in well differentiated intestinal type adenocarcinomas as 
compared to the diffuse carcinomas. The results of this study are in agreement with Ho's finding 
of multiple expression in advanced cases. This multiple expression may reflect increasing 
"dedifferentiation" of the carcinomas. Alternatively the aberrant mucin genes may alter the 
biology of the cell so that it has greater potential for malignant transformation and metastasis. 
Is there a role for mucins in the detection of precancerous/ early cancerous 
states? 
As a result of the alterations that occur in mucin gene expression in disease states there has been 
an increasing interest in mucins as possible markers to detect pre-malignant states or early 
malignancy. Tumour markers useful for diagnosing gastric carcinoma at an early stage have not 
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been identified. Carcino-embryonic antigen and CA19-9 are markers that have been assessed in 
the past, but they are most often elevated in patients with incurable disease, and are, therefore, 
unsuitable for early detection of disease [107]. The association between mucin abnormalities and 
malignancy has been well described, and the identification of different mucin genes in humans 
has important applications for cancer research [19] in the detection and treatment of carcinomas 
in general, and also in their role as possible diagnostic and therapeutic agents [107] . 
This study was unable to show that using MUC antibodies on gastric biopsies has predictive 
value for detection of precancerous lesions. The mucins in gastritis did not differ significantly 
from those of normal controls. Intestinal metaplasia and dysplasia showed a similar staining 
pattern (increased MUC2 and MUC3), and MUC immunohistochemistry is therefore of no use in 
separating the two conditions. It is possible that in the future screening tests for MUC2 and 3 
may alert the clinician to the presence of intestinal metaplasia, but even if this were the case 
intestinal metaplasia occurs in association with both benign and malignant conditions, and 
abnormal MUC expression is not a sensitive indicator of precancerous conditions. Advanced 
carcinomas in this study showed increased expression of different mucin genes, but by the time 
this amount of alteration in the mucin genes is present the carcinoma is already far advanced. At 
this point in time MUC antibodies are not freely available, and routine use of these antibodies, 
should they become available, is not a cost effective exercise. 
The association of Helicobacter pylori with gastric disease 
Of note is a very high prevalence of Helicobacter pylori in the population studied. As with other 
studies, this study found that the Helicobacter pylori did not adhere to the gastric epithelium 
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which showed changes of intestinal metaplasia, although the organisms could be found on 
adjacent "normal" epithelium. A relationship has been suggested between Helicobacter pylori 
infection and gastric carcinoma [51,82,108-112], particularly of the intestinal type. All the early 
intestinal type adenocarcinomas in this study, and 2 of 5 advanced intestinal adenocarcinomas 
had associated Helicobacter pylori, but none could be found in the diffuse adenocarcinomas. This 
may be because advanced malignancy, particularly diffuse adenocarcinoma presents an 
unfavourable environment for Helicobacter pylori, and this finding has been supported by other 
studies [25]. The organisms were most likely present earlier in the disease process in these 
stomachs. Metaplastic changes and advanced carcinoma are inhospitable to Helicobacter pylori, 
but it is uncertain if changes in mucin gene expression are implicated. Further investigations will 
be needed to assess the effect that Helicobacter pylori has on MUC gene expression, as well as 
the effect that changes in MUC gene expression have on Helicobacter pylori,and its ability to 
adhere to altered epithelium. 
CONCLUSIONS 
It can be concluded that specific human mucins are expressed in normal stomach, and that these 
become significantly altered in disease states. Foetal stomachs express the same mucin genes as 
adult stomach, but expression only begins from the second trimester. The mucins in gastritis do 
not differ significantly from the normal controls. Intestinal metaplasia and dysplasia show a 
similar staining pattern (increased MUC 2 and 3), and MUC expression is therefore of no use in 
separating the two conditions. 
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Mucin immunoreactivity appears to be switched off in early cancers, an observation which needs 
to be investigated further, while advanced intestinal type and diffuse adenocarcinomas show 
expression of multiple genes. 
The clinical, pathological and biological significance of these patterns of mucin staining remains 
to be elucidated. 
47 
APPENDIX 
SUPPLIERS OF ANTIBODIES USED IN THE IMMUNOHISTOCHEMICAL STUDY 
Biotinylated rabbit-anti-mouse antibody - Dako, Copenhagen, Denmark. 
Biotinylated swine-anti-rabbit antibody- Dako, Copenhagen, Denmark. 
Biotinylated rabbit-anti-chicken antibody - Biogenesis, Poole, U.K. 
Strep-avidin HRP - Dako, Copenhagen, Denmark. 
MUCJ - 7 antibodies were supplied by Professor Sam B. Ho, University of Minnesota and 
Veterans Administration Medical Center, Minneapolis (Table 4). 
Mucin gene Name Type 
MUCJ 139H2 MousemAba 
MUC2 MRP RabbitpAbb 
MUC3 M3P RabbitpAb 
MUC4 M4P ChickenpAb 
MUC5 M5P ChickenpAb 
MUC6 M6P ChickenpAb 
MUC5 +MUC6 FHF RabbitpAb 
MUC7 M7P ChickenpAb 
Table 4. Mucin core peptide antibodies 
• mAb = monoclonal antibody 
b pAb = polyclonal antibody 
[Ref: 12 and personal correspondence] 
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